431 related articles for article (PubMed ID: 30524273)
1. Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment.
Andrade S; Ramalho MJ; Pereira MDC; Loureiro JA
Front Pharmacol; 2018; 9():1261. PubMed ID: 30524273
[TBL] [Abstract][Full Text] [Related]
2. Brain targeting based nanocarriers loaded with resveratrol in Alzheimer's disease: A review.
Jalili C; Kiani A; Gholami M; Bahrehmand F; Fakhri S; Kakehbaraei S; Kakebaraei S
IET Nanobiotechnol; 2023 May; 17(3):154-170. PubMed ID: 36949020
[TBL] [Abstract][Full Text] [Related]
3. The uses of resveratrol for neurological diseases treatment and insights for nanotechnology based-drug delivery systems.
Fonseca-Santos B; Chorilli M
Int J Pharm; 2020 Nov; 589():119832. PubMed ID: 32877730
[TBL] [Abstract][Full Text] [Related]
4. ApoE-modified liposomes encapsulating resveratrol and salidroside alleviate manifestations of Alzheimer's disease in APP/PS-1 mice.
Chen MH; Liu XZ; Qu XW; Guo RB; Zhang L; Kong L; Yu Y; Liu Y; Zang J; Li XY; Li XT
Drug Dev Ind Pharm; 2023 Sep; 49(9):559-571. PubMed ID: 37649422
[TBL] [Abstract][Full Text] [Related]
5. Polyphenols and Their Impact on the Prevention of Neurodegenerative Diseases and Development.
Grabska-Kobyłecka I; Szpakowski P; Król A; Książek-Winiarek D; Kobyłecki A; Głąbiński A; Nowak D
Nutrients; 2023 Aug; 15(15):. PubMed ID: 37571391
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticles improved resveratrol brain delivery and its therapeutic efficacy against intracerebral hemorrhage.
Mo Y; Duan L; Yang Y; Liu W; Zhang Y; Zhou L; Su S; Lo PC; Cai J; Gao L; Liu Q; Chen X; Yang C; Wang Q; Chen T
Nanoscale; 2021 Feb; 13(6):3827-3840. PubMed ID: 33565555
[TBL] [Abstract][Full Text] [Related]
7. Brain targeted peptide-functionalized chitosan nanoparticles for resveratrol delivery: Impact on insulin resistance and gut microbiota in obesity-related Alzheimer's disease.
Yang L; Wang Y; Li Z; Wu X; Mei J; Zheng G
Carbohydr Polym; 2023 Jun; 310():120714. PubMed ID: 36925241
[TBL] [Abstract][Full Text] [Related]
8. Nanotechnology-based formulations for resveratrol delivery: Effects on resveratrol in vivo bioavailability and bioactivity.
Santos AC; Pereira I; Pereira-Silva M; Ferreira L; Caldas M; Collado-González M; Magalhães M; Figueiras A; Ribeiro AJ; Veiga F
Colloids Surf B Biointerfaces; 2019 Aug; 180():127-140. PubMed ID: 31035056
[TBL] [Abstract][Full Text] [Related]
9. Neuronal mitochondria-targeted therapy for Alzheimer's disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems.
Han Y; Chu X; Cui L; Fu S; Gao C; Li Y; Sun B
Drug Deliv; 2020 Dec; 27(1):502-518. PubMed ID: 32228100
[TBL] [Abstract][Full Text] [Related]
10. Recent Developments in Nanoparticle Formulations for Resveratrol Encapsulation as an Anticancer Agent.
Ali M; Benfante V; Di Raimondo D; Salvaggio G; Tuttolomondo A; Comelli A
Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38256959
[TBL] [Abstract][Full Text] [Related]
11. Recent progress in nanotechnology-based drug carriers for resveratrol delivery.
Li C; Wang Z; Lei H; Zhang D
Drug Deliv; 2023 Dec; 30(1):2174206. PubMed ID: 36852655
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol-Laden Nano-Systems in the Cancer Environment: Views and Reviews.
Sarfraz M; Arafat M; Zaidi SHH; Eltaib L; Siddique MI; Kamal M; Ali A; Asdaq SMB; Khan A; Aaghaz S; Alshammari MS; Imran M
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760469
[TBL] [Abstract][Full Text] [Related]
13. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
Sa P; Singh P; Dilnawaz F; Sahoo SK
Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic nanoplatforms and delivery strategies for neurological disorders.
Kang YJ; Cutler EG; Cho H
Nano Converg; 2018 Nov; 5(1):35. PubMed ID: 30499047
[TBL] [Abstract][Full Text] [Related]
15. Neuronal mitochondria-targeted delivery of curcumin by biomimetic engineered nanosystems in Alzheimer's disease mice.
Gao C; Wang Y; Sun J; Han Y; Gong W; Li Y; Feng Y; Wang H; Yang M; Li Z; Yang Y; Gao C
Acta Biomater; 2020 May; 108():285-299. PubMed ID: 32251785
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of oral bioavailability and anti-Parkinsonian efficacy of resveratrol through a nanocrystal formulation.
Xiong S; Liu W; Zhou Y; Mo Y; Liu Y; Chen X; Pan H; Yuan D; Wang Q; Chen T
Asian J Pharm Sci; 2020 Jul; 15(4):518-528. PubMed ID: 32952674
[TBL] [Abstract][Full Text] [Related]
17. Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases.
Teixeira MI; Lopes CM; Amaral MH; Costa PC
Colloids Surf B Biointerfaces; 2023 Jan; 221():112999. PubMed ID: 36368148
[TBL] [Abstract][Full Text] [Related]
18. Galactosylated PLGA nanoparticles for the oral delivery of resveratrol: enhanced bioavailability and in vitro anti-inflammatory activity.
Siu FY; Ye S; Lin H; Li S
Int J Nanomedicine; 2018; 13():4133-4144. PubMed ID: 30038494
[TBL] [Abstract][Full Text] [Related]
19. Formulation design, optimization and
Hasija R; Chaurasia S; Gupta S
Pharm Dev Technol; 2021 Nov; 26(9):953-966. PubMed ID: 34374616
[TBL] [Abstract][Full Text] [Related]
20. Resveratrol Nanoparticle Complex: Potential Therapeutic Applications in Myocardial Ischemia Reperfusion Injury.
Zhou H; Shan Y; Tong F; Zhang Y; Tang J; Shen R; Chen D
J Biomed Nanotechnol; 2020 Mar; 16(3):382-389. PubMed ID: 32493548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
